New lupus drug candidate cenerimod tested in chinese patients

NCT ID NCT07266090

Ongoing Disease control Sponsor: Viatris Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This phase 2 trial is testing an experimental drug called cenerimod in 15 Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants take a 4 mg tablet daily for 12 months while continuing their usual lupus medications. The study focuses on safety, how the body processes the drug, and its effect on immune cells. It does not compare cenerimod to a placebo or other treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenerimod (an experimental oral drug that may reduce immune cell activity)
What this could lead to: If it works, this could point toward a new treatment option for Chinese patients with moderate-to-severe lupus.
What could go wrong: This is a small, early-phase study with only 15 participants and no placebo group. It primarily looks at safety and drug levels, not whether the drug actually improves lupus symptoms. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLE - SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, 471003, China
First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330200, China
Jiujiang NO.1 peple's hospital

Jiujiang, Jiangxi, 332000, China
Peking Union Medical College Hospital

Beijing, 100010, China
The First Affiliated Hospital Of Jinan University

Guangzhou, Guangdong, 510630, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.